University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 31 of 35

COMPLETED Phase 1

Effect of Cocoa Flavanols on Vascular Function

NCT00553774

COMPLETED

Adherence and the Economics of Colon Cancer Screening

NCT00705731

COMPLETED

The Impact of Lymphedema on Breast Cancer Survivors

NCT00769821

COMPLETED

MEG and DTI of Neural Function and Connectivity in Traumatic Brain Injury

NCT01298557

COMPLETED NA

Evaluating a Distance Learning Asthma Education Program for Pediatricians (The DALI Study)

NCT00815724

COMPLETED

Sonographic Assessment and Visualization of Ectopics in Emergency Medicine

NCT01322958

COMPLETED Phase 1

Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus

NCT00501709

COMPLETED

Biomarker Study for Heart Failure in Children With Single Ventricle Physiology

NCT00571233

COMPLETED Phase 3

A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

NCT00501696

COMPLETED Phase 1

Dyspnea Self-Management: Internet or Face-to-Face

NCT00461162

COMPLETED Phase 1

Cotinine Metabolism in Infants and Children

NCT00994591

COMPLETED

Comparison of CT Angiography With Conventional Angiography and Intravascular Ultrasound in Heart Transplant Patients

NCT00723281

COMPLETED Phase 3

Educational Program to Improve Heart Failure Outcomes in Adults Living in Rural Areas

NCT00415545

COMPLETED NA

Study on Use of Xylitol-wipes to Prevent Dental Caries

NCT01468727

TERMINATED NA

Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy

NCT02669290

COMPLETED Phase 2

Craving and Lifestyle Management Through Mindfulness Study

NCT01250509

COMPLETED Phase 4

Induction of Labor With a Foley Balloon Catheter: Inflation With 30ml Compared to 60ml

NCT00451308

COMPLETED Phase 1

Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge

NCT00373412

COMPLETED Phase 1

Sorafenib and RAD001 Renal Cell Carcinoma

NCT00384969

COMPLETED Phase 1

Yoga for the Treatment of Metabolic Syndrome

NCT00605436

COMPLETED NA

HIV Testing Strategies in the Perinatal Setting

NCT00503308

COMPLETED NA

Reducing Disparities in Diabetes Risk Through Lifestyle Changes in Community Settings

NCT00770926

TERMINATED

" Patients Attitude Towards Physicians and Health Screening Issues Among First Generation Asian-Indian Immigrants to United States".

NCT00378430

COMPLETED Phase 4

Valganciclovir to Reduce T Cell Activation in HIV Infection

NCT00264290

COMPLETED Phase 1

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

NCT00390156

COMPLETED

MR Imaging of Knee Osteoarthritis and Acute Knee Injuries

NCT00504114

COMPLETED NA

Intensive Intervention for Smokers - 6

NCT00217984

COMPLETED Phase 2

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

NCT00416403

COMPLETED Phase 2

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

NCT00501943

COMPLETED Phase 1

GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer

NCT00305669

COMPLETED Phase 1

A Mindfulness Based Approach to HIV Treatment Side Effects

NCT00312936

TERMINATED Phase 1

Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery

NCT00410774

COMPLETED NA

The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA

NCT00739921

COMPLETED

A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome

NCT00862576

COMPLETED

The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry

NCT00328133

COMPLETED NA

The Health in Pregnancy (HIP) Study

NCT00540319

TERMINATED Phase 4

Protocols for Improved in Vitro Fertilization (IVF) Outcomes

NCT00334243

TERMINATED Phase 2

Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo

NCT00352651

COMPLETED Phase 3

Educational Intervention on Weight Management in Chinese-American Children

NCT00522964

COMPLETED NA

Impact of Using Mini-Bronchoalveolar Lavage as a Diagnostic Test for Ventilator-Associated Pneumonia

NCT00319644

COMPLETED NA

Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement

NCT00333437

COMPLETED

Does Bone Structure Explain the Increased Fracture Risk in Type II Diabetes Patients? A Pilot Study

NCT00703417

COMPLETED Phase 1

Opioid and Cannabinoid Pharmacokinetic Interactions

NCT00308555

TERMINATED

Mechanisms of Exacerbation of Asthma

NCT00594750

TERMINATED

The Use of Tissue Oxygen Monitoring in Critically Injured Patients

NCT00328341

TERMINATED Phase 1

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

NCT00616122

COMPLETED

Validation of Dietary Calcium Questionnaires Using Diet Records

NCT00512733

COMPLETED Phase 1

Alpha Lipoic Acid and Polycystic Ovary Syndrome

NCT00505427

TERMINATED NA

Modafinil-Alcohol Interactions in Healthy Volunteers

NCT00305292

COMPLETED Phase 4

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

NCT00504166

← Previous Page 31 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.